Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 9Ovarian Neoplasms 3Lymphoma 3Carcinoma, Ovarian Epithelial 3Uveal Melanoma 2Sarcoma 2Rectal Neoplasms 2Prostatic Neoplasms 2Melanoma 2Leukemia 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Choroid Plexus Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Lobular 2Carcinoma, Intraductal, Noninfiltrating 2Breast Neoplasms, Male 2Breast Cancer Patients 2Astrocytoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unspecified Childhood Solid Tumor, Protocol Specific 1Small Cell Lung Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Verteporfin 1Radiotherapy 1Gelclair 1Etoposide 1Erlotinib Hydrochloride 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Familial ependymoma × Amplified Fragment Length Polymorphism Analysis × Clear all
NCT00360854 2013-09-20

Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma

National Cancer Institute (NCI)

Phase 1 Unknown
48 enrolled
CNS

Familial ependymoma, Astrocytoma, Medulloblastoma, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡